SCHEMBL6879720

SCHEMBL6879720

Cc1nc(C)c(Cl)c(CNCc2ccc(O)cn2)n1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
PDCD1 Q15116 1/20 0.30
CD274 Q9NZQ7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6882948 0.80 TSHR (0.38) ESR1ESR2
Bromide SCHEMBL6876839 0.79 TSHR (0.37) ESR1ESR2
SCHEMBL6879716 0.74 METAP2 (0.39) ESR1ESR2
SCHEMBL28769415 0.64 ESR1 (0.46) ESR1ESR2
SCHEMBL19555318 0.62 ESR1 (0.41) ESR1ESR2
SCHEMBL6743052 0.62 ESR1 (0.49) ESR1
SCHEMBL2644755 0.61 NPSR1 (0.53) ESR1ESR2
SCHEMBL23963097 0.60 ESR1 (0.46) ESR1ESR2
SCHEMBL24468090 0.60 PTK2 (0.41)
SCHEMBL30841920 0.60 PTK2 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040158066-A1 Novel pyridylmethylaminopyrimidines ALTANA PHARMA AG (DE) 2004-08-12 US disclosed
EP-1395592-A1 NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES ALTANA Pharma AG (DE) 2004-03-10 EP disclosed
WO-2002094831-A1 NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES ALTANA PHARMA AG (DE) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158066-A1 Novel pyridylmethylaminopyrimidines PGLS, PLPBP, PDXK ESR1 3095/4885ESR2 3862/4885PDCD1 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.